Dominick J. Angiolillo

Author

Also Known As

Angel Cequier, Angiolillo, Dominick J., Angiolillo, Dominick J.; Division of Cardiology, University of Florida, Shands Jacksonville, Jacksonville, Florida, Antonio Gonzalez, Camino Bañuelos, D ANGIOLILLO, D Angiolillo, D J Angiolillo, D. Angiolillo, D. Erlinge

1.1K

Publications

52.8K

Citations

109

H-Index

115

Concepts

All Affiliations

University of Florida Florida College Brigham and Women's Hospital Hospital Clínico San Carlos Harvard University

About

Dominick J. Angiolillo is an author at University of Florida specializing in medicine, cardiovascular disease, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	135	12.2K
2	Public Health	21	28	2.7K
3	Health Sciences	12	12	332
4	Engineering	2	2	40
5	Allergy	1	1	16

Dominick J. Angiolillo

283

Publications

28.9K

Citations

H-Index

Page 1

	Year	Citations
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate Laurent Bonello, Udaya S. Tantry, Rossella Marcucci, Journal of the American College of Cardiology ThrombopoiesisThrombosisSignal TransductionBiochemistryFuture Directions	2010	1.1K
Ticagrelor with or without Aspirin in High-Risk Patients after PCI Roxana Mehran, Usman Baber, Samin K. Sharma, New England Journal of Medicine	2019	957
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding Udaya S. Tantry, Laurent Bonello, Dániel Aradi, Journal of the American College of Cardiology ThrombopoiesisThrombosisCardiovascular DiseaseOn-treatment Platelet ReactivityMedicine	2013	892
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention Stephen D. Wiviott, Dietmar Trenk, Andrew L. Frelinger, Circulation	2007	874
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events Deepak L. Bhatt, Gregg W. Stone, Kenneth W. Mahaffey, New England Journal of Medicine	2013	818
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes Stefanie Schüpke, Franz‐Josef Neumann, Maurizio Menichelli, New England Journal of Medicine	2019	756
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 Stephen D. Wiviott, Eugene Braunwald, Dominick J. Angiolillo, Circulation	2008	751
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents Dietmar Trenk, Gregg W. Stone, Meinrad Gawaz, Journal of the American College of Cardiology Percutaneous Coronary InterventionThrombosisCardiovascular DiseaseBlood PlateletPharmacology	2012	613
Platelet Inhibition with Cangrelor in Patients Undergoing PCI Robert A. Harrington, Gregg W. Stone, Steven E. McNulty, New England Journal of Medicine	2009	613
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk Philip Urban, Roxana Mehran, Róisín Colleran, European Heart Journal	2019	540

Page 1